condition dictated ( table 2 ). The Neuroaid dose received was 4 tablets, 3 times per day. Treatment was initiated between 1 week and 6 months after stroke, and given to each patient for 2-3 months.
Cases presented with neurological impairments affecting motor, balance, speech and visual functions. These were assessed during initial examination and confirmed with imagery ( table 1 ) .
The patients showed a good tolerability to the treatment. Only 1 mild adverse event was reported, with patient No. 4 reporting diarrhea after starting Neuroaid. Treatment was reduced, and then progressively increased to full dosage within a week.
On follow-up, all cases reported improvements over the period in which they received Neuroaid. There were 6 cases of patients showing full recovery, 3 cases of good or moderate recovery and 1 case of poor recovery. Significant improvements were recorded in motor, visual, speech and cognitive functions ( table 1 ). Motor skills: the 8 patients with motor deficits improved in the strength of their upper and lower extremities, and their ability to walk; motor disabilities fully resolved in 6 patients. Balance: the 3 patients showing difficulties in their balance recovered. Vision: the diplopia and hemianopia in 5 patients resolved. Speech: 4 patients reported improvements in speech disabilities, including expressive aphasia and anomia; after 3 months, 2 had fully recovered from their speech impairments.
The impact of Neuroaid treatment cannot be differentiated from the contribution of natural recovery, medStroke is a leading cause of death and disability worldwide [1] . Many patients only make a partial or poor recovery after stroke, and the major burden of stroke is chronic disability [2] . To date, no effective treatment has been found for reducing stroke-induced disabilities.
Neuroaid originates from Traditional Chinese Medicine. It has been developed to aid post-stroke recovery, and has recently been approved in 7 countries, including Singapore.
Early trials of Neuroaid, performed in China on 605 patients in 2000, established its safety and demonstrated a positive effect on the recovery of independence and motor functions. Patients receiving Neuroaid were found to be 2.4 times more likely to achieve independence at 1 month after stroke than the control group [3, 4] . More recently, safety trials showed that Neuroaid, taken either alone or in combination with aspirin, does not modify hemostasis, hematology and biochemistry in normal subjects and stroke patients [6] . Additional double-blind randomized placebo-controlled trials are ongoing in Asia [5] . This is a case description of 10 patients who took Neuroaid after ischemic stroke onset. All patients were seen in a private clinic at Mount Alvernia Hospital in Singapore and in the Neurology Outpatient Clinic for subsequent follow-up.
Neuroaid was given as an add-on to other medications, including antiplatelet, anticoagulant (warfarin), lipid-lowering, antihypertensive, diabetic and antidepressant medications, which were used as the patient's It is consistent with late-stage recovery data shown in early clinical trials. Although the exact mechanism is not well understood, initial laboratory studies suggest improvements in brain neuroplasticity and neuroprotection. Larger double-blind placebo-controlled studies will provide more comprehensive data on Neuroaid in the future. ication and physiotherapy effects. However, all cases reported improvements. Interestingly, 3 patients started Neuroaid treatment at a later stage of stroke recovery. In particular, patient No. 8 started Neuroaid 6 months after reaching a plateau in his recovery, and after this continued to experience improvements in his speech and cognitive abilities. Another 2 patients (No. 6 and 7) started Neuroaid 1 month after their strokes, and both recovered significantly.
These findings support the safety of Neuroaid and its positive effect on the recovery of the post-stroke patient. 
